Expanding role of lenalidomide in hematologic malignancies

Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia...

Full description

Bibliographic Details
Main Authors:	Ghosh, Nilanjan, Grunwald, Michael R, Fasan, Omotayo, Bhutani, Manisha
Format:	Online
Language:	English
Published:	Dove Medical Press 2015
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427066/

id	pubmed-4427066
recordtype	oai_dc
spelling	pubmed-44270662015-05-21 Expanding role of lenalidomide in hematologic malignancies Ghosh, Nilanjan Grunwald, Michael R Fasan, Omotayo Bhutani, Manisha Review Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia. The mode of action includes immunomodulatory, anti-inflammatory, antiangiogenic, and antiproliferative mechanisms. The antitumor effect is a result of direct interference of key pathways in tumor cells and indirect modulation of the tumor microenvironment. There has been no recent collective review on lenalidomide in multiple myeloma, myelodysplastic syndrome/acute myeloid leukemia, and lymphoma. This review summarizes the results of current clinical studies of lenalidomide, alone and in combination with other agents, as a therapeutic option for various hematologic malignancies. Dove Medical Press 2015-05-02 /pmc/articles/PMC4427066/ /pubmed/25999761 http://dx.doi.org/10.2147/CMAR.S81310 Text en © 2015 Ghosh et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Ghosh, Nilanjan Grunwald, Michael R Fasan, Omotayo Bhutani, Manisha
spellingShingle	Ghosh, Nilanjan Grunwald, Michael R Fasan, Omotayo Bhutani, Manisha Expanding role of lenalidomide in hematologic malignancies
author_facet	Ghosh, Nilanjan Grunwald, Michael R Fasan, Omotayo Bhutani, Manisha
author_sort	Ghosh, Nilanjan
title	Expanding role of lenalidomide in hematologic malignancies
title_short	Expanding role of lenalidomide in hematologic malignancies
title_full	Expanding role of lenalidomide in hematologic malignancies
title_fullStr	Expanding role of lenalidomide in hematologic malignancies
title_full_unstemmed	Expanding role of lenalidomide in hematologic malignancies
title_sort	expanding role of lenalidomide in hematologic malignancies
description	Lenalidomide is an immunomodulatory agent that has been approved by the US Food and Drug Administration for treatment of multiple myeloma, deletion 5q myelodysplastic syndrome, and mantle cell lymphoma. In addition, it has clinical activity in lymphoproliferative disorders and acute myeloid leukemia. The mode of action includes immunomodulatory, anti-inflammatory, antiangiogenic, and antiproliferative mechanisms. The antitumor effect is a result of direct interference of key pathways in tumor cells and indirect modulation of the tumor microenvironment. There has been no recent collective review on lenalidomide in multiple myeloma, myelodysplastic syndrome/acute myeloid leukemia, and lymphoma. This review summarizes the results of current clinical studies of lenalidomide, alone and in combination with other agents, as a therapeutic option for various hematologic malignancies.
publisher	Dove Medical Press
publishDate	2015
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4427066/
_version_	1613221737566044160

Expanding role of lenalidomide in hematologic malignancies

Similar Items